Drugs / INVAC-1, A DOUBLE STRANDED DNA PLASMID VACCINE CONSTRUCT ENCODING UBIQUITIN-HUMAN TELOMERASE REVERSE TRANSCRIPTASE (HTERT) FUSION PROTEIN
INVAC-1, A DOUBLE STRANDED DNA PLASMID VACCINE CONSTRUCT ENCODING UBIQUITIN-HUMAN TELOMERASE REVERSE TRANSCRIPTASE (HTERT) FUSION PROTEIN
also known as
INVAC-1
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04515043 | Oct → Dec 2020 | cancer | Invectys | Completed | No outcome recorded |
| Phase 1 | NCT02301754 | Nov 2014 → Feb 2018 | cancer | Invectys | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03265717 | Jul 2018 → Jun 2020 | B-cell chronic lymphocytic leukemia | Invectys | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INVAC-1, A DOUBLE STRANDED DNA PLASMID VACCINE CONSTRUCT ENCODING UBIQUITIN-HUMAN TELOMERASE REVERSE TRANSCRIPTASE (HTERT) FUSION PROTEIN | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594561 ↗ |
| Known as | INVAC-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03265717 ↗ |
| Modality | Vaccine | “INVAC-1 vaccine” NCT04515043 ↗ |